Leveraging expedited programs in oncology: How accelerated approval helps drug developers get cancer drugs to patients faster
The FDA’s expedited programs accommodate shortened drug development timelines for therapies intended to treat serious diseases, making them pivotal opportunities in oncology. We spoke to Fortrea’s experts to understand the latest best practices for oncology drug developers navigating the accelerated approval pathway.
